Stevanato Group S.p.A. (NYSE: STVN) Stock Competitors & Peer Comparison
See STVN's competitors and their performance on the NYSE and across the wider stock market.
Peer Comparison Table: Medical - Instruments & Supplies Industry
Detailed financial metrics including price, market cap, P/E ratio, and more for STVN and its NYSE peers.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| STVN | $22.03 | +3.89% | 5.9B | 32.92 | $0.66 | +0.29% |
| ISRG | $391.17 | -0.00% | 140.5B | 41.34 | $9.62 | N/A |
| BDXA | $59.24 | -2.24% | 55.9B | 45.70 | $1.30 | +2.00% |
| BDX | $189.53 | +4.85% | 51.7B | 14.43 | $13.00 | +2.00% |
| MDLN | $33.04 | -3.18% | 28.7B | 24.85 | $1.36 | N/A |
| WST | $357.68 | +3.20% | 24.8B | 44.29 | $7.97 | +0.25% |
| HOLX | $76.01 | +0.00% | 17B | 31.54 | $2.41 | N/A |
| SOLV | $89.31 | +2.13% | 15.2B | 12.37 | $7.10 | N/A |
| COO | $76.82 | +1.40% | 15B | 16.83 | $4.56 | N/A |
| BAX | $26.40 | +1.77% | 13.8B | 12.82 | $2.08 | +0.75% |
Stock Comparison
Intuitive Surgical, Inc. (NASDAQ: ISRG)
STVN vs ISRG Comparison August 2026
Stevanato Group S.p.A. (NYSE: STVN) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, STVN stands at 5.9B. In comparison, ISRG has a market cap of 140.5B. Regarding current trading prices, STVN is priced at $22.03 on the NYSE, while ISRG trades at $391.17.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
STVN currently has a P/E ratio of 32.92, whereas ISRG's P/E ratio is 41.34. In terms of profitability, STVN's ROE is +0.09%, compared to ISRG's ROE of +0.18%. Regarding short-term risk, STVN is more volatile compared to ISRG. This indicates higher risk in terms of short-term price fluctuations for STVN.Check ISRG's competition here
Becton, Dickinson and Company (NYSE: BDXA)
STVN vs BDXA Comparison August 2026
Stevanato Group S.p.A. (NYSE: STVN) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, STVN stands at 5.9B. In comparison, BDXA has a market cap of 55.9B. Regarding current trading prices, STVN is priced at $22.03 on the NYSE, while BDXA trades at $59.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
STVN currently has a P/E ratio of 32.92, whereas BDXA's P/E ratio is 45.70. In terms of profitability, STVN's ROE is +0.09%, compared to BDXA's ROE of +0.04%. Regarding short-term risk, STVN is less volatile compared to BDXA. This indicates lower risk in terms of short-term price fluctuations for STVN.Check BDXA's competition here
Becton, Dickinson and Company (NYSE: BDX)
STVN vs BDX Comparison August 2026
Stevanato Group S.p.A. (NYSE: STVN) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, STVN stands at 5.9B. In comparison, BDX has a market cap of 51.7B. Regarding current trading prices, STVN is priced at $22.03 on the NYSE, while BDX trades at $189.53.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
STVN currently has a P/E ratio of 32.92, whereas BDX's P/E ratio is 14.43. In terms of profitability, STVN's ROE is +0.09%, compared to BDX's ROE of +0.04%. Regarding short-term risk, STVN is more volatile compared to BDX. This indicates higher risk in terms of short-term price fluctuations for STVN.Check BDX's competition here
Medline Inc. (NASDAQ: MDLN)
STVN vs MDLN Comparison August 2026
Stevanato Group S.p.A. (NYSE: STVN) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, STVN stands at 5.9B. In comparison, MDLN has a market cap of 28.7B. Regarding current trading prices, STVN is priced at $22.03 on the NYSE, while MDLN trades at $33.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
STVN currently has a P/E ratio of 32.92, whereas MDLN's P/E ratio is 24.85. In terms of profitability, STVN's ROE is +0.09%, compared to MDLN's ROE of +0.05%. Regarding short-term risk, STVN is more volatile compared to MDLN. This indicates higher risk in terms of short-term price fluctuations for STVN.Check MDLN's competition here
West Pharmaceutical Services, Inc. (NYSE: WST)
STVN vs WST Comparison August 2026
Stevanato Group S.p.A. (NYSE: STVN) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, STVN stands at 5.9B. In comparison, WST has a market cap of 24.8B. Regarding current trading prices, STVN is priced at $22.03 on the NYSE, while WST trades at $357.68.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
STVN currently has a P/E ratio of 32.92, whereas WST's P/E ratio is 44.29. In terms of profitability, STVN's ROE is +0.09%, compared to WST's ROE of +0.19%. Regarding short-term risk, STVN is more volatile compared to WST. This indicates higher risk in terms of short-term price fluctuations for STVN.Check WST's competition here
Hologic, Inc. (NASDAQ: HOLX)
STVN vs HOLX Comparison August 2026
Stevanato Group S.p.A. (NYSE: STVN) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, STVN stands at 5.9B. In comparison, HOLX has a market cap of 17B. Regarding current trading prices, STVN is priced at $22.03 on the NYSE, while HOLX trades at $76.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
STVN currently has a P/E ratio of 32.92, whereas HOLX's P/E ratio is 31.54. In terms of profitability, STVN's ROE is +0.09%, compared to HOLX's ROE of +0.11%. Regarding short-term risk, STVN is more volatile compared to HOLX. This indicates higher risk in terms of short-term price fluctuations for STVN.Check HOLX's competition here
Solventum Corporation (NYSE: SOLV)
STVN vs SOLV Comparison August 2026
Stevanato Group S.p.A. (NYSE: STVN) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, STVN stands at 5.9B. In comparison, SOLV has a market cap of 15.2B. Regarding current trading prices, STVN is priced at $22.03 on the NYSE, while SOLV trades at $89.31.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
STVN currently has a P/E ratio of 32.92, whereas SOLV's P/E ratio is 12.37. In terms of profitability, STVN's ROE is +0.09%, compared to SOLV's ROE of +0.29%. Regarding short-term risk, STVN is more volatile compared to SOLV. This indicates higher risk in terms of short-term price fluctuations for STVN.Check SOLV's competition here
The Cooper Companies, Inc. (NASDAQ: COO)
STVN vs COO Comparison August 2026
Stevanato Group S.p.A. (NYSE: STVN) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, STVN stands at 5.9B. In comparison, COO has a market cap of 15B. Regarding current trading prices, STVN is priced at $22.03 on the NYSE, while COO trades at $76.82.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
STVN currently has a P/E ratio of 32.92, whereas COO's P/E ratio is 16.83. In terms of profitability, STVN's ROE is +0.09%, compared to COO's ROE of +0.03%. Regarding short-term risk, STVN is more volatile compared to COO. This indicates higher risk in terms of short-term price fluctuations for STVN.Check COO's competition here
Baxter International Inc. (NYSE: BAX)
STVN vs BAX Comparison August 2026
Stevanato Group S.p.A. (NYSE: STVN) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, STVN stands at 5.9B. In comparison, BAX has a market cap of 13.8B. Regarding current trading prices, STVN is priced at $22.03 on the NYSE, while BAX trades at $26.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
STVN currently has a P/E ratio of 32.92, whereas BAX's P/E ratio is 12.82. In terms of profitability, STVN's ROE is +0.09%, compared to BAX's ROE of -0.17%. Regarding short-term risk, STVN is more volatile compared to BAX. This indicates higher risk in terms of short-term price fluctuations for STVN.Check BAX's competition here
Becton, Dickinson and Company (NYSE: BDXB)
STVN vs BDXB Comparison August 2026
Stevanato Group S.p.A. (NYSE: STVN) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, STVN stands at 5.9B. In comparison, BDXB has a market cap of 13.7B. Regarding current trading prices, STVN is priced at $22.03 on the NYSE, while BDXB trades at $48.16.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
STVN currently has a P/E ratio of 32.92, whereas BDXB's P/E ratio is 7.60. In terms of profitability, STVN's ROE is +0.09%, compared to BDXB's ROE of +0.04%. Regarding short-term risk, STVN is more volatile compared to BDXB. This indicates higher risk in terms of short-term price fluctuations for STVN.Check BDXB's competition here
Repligen Corporation (NASDAQ: RGEN)
STVN vs RGEN Comparison August 2026
Stevanato Group S.p.A. (NYSE: STVN) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, STVN stands at 5.9B. In comparison, RGEN has a market cap of 10B. Regarding current trading prices, STVN is priced at $22.03 on the NYSE, while RGEN trades at $184.48.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
STVN currently has a P/E ratio of 32.92, whereas RGEN's P/E ratio is 97.98. In terms of profitability, STVN's ROE is +0.09%, compared to RGEN's ROE of +0.02%. Regarding short-term risk, STVN is less volatile compared to RGEN. This indicates lower risk in terms of short-term price fluctuations for STVN.Check RGEN's competition here
Avantor, Inc. (NYSE: AVTR)
STVN vs AVTR Comparison August 2026
Stevanato Group S.p.A. (NYSE: STVN) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, STVN stands at 5.9B. In comparison, AVTR has a market cap of 9.5B. Regarding current trading prices, STVN is priced at $22.03 on the NYSE, while AVTR trades at $14.34.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
STVN currently has a P/E ratio of 32.92, whereas AVTR's P/E ratio is 16.44. In terms of profitability, STVN's ROE is +0.09%, compared to AVTR's ROE of -0.10%. Regarding short-term risk, STVN is less volatile compared to AVTR. This indicates lower risk in terms of short-term price fluctuations for STVN.Check AVTR's competition here
AptarGroup, Inc. (NYSE: ATR)
STVN vs ATR Comparison August 2026
Stevanato Group S.p.A. (NYSE: STVN) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, STVN stands at 5.9B. In comparison, ATR has a market cap of 8.5B. Regarding current trading prices, STVN is priced at $22.03 on the NYSE, while ATR trades at $133.21.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
STVN currently has a P/E ratio of 32.92, whereas ATR's P/E ratio is 23.24. In terms of profitability, STVN's ROE is +0.09%, compared to ATR's ROE of +0.14%. Regarding short-term risk, STVN is more volatile compared to ATR. This indicates higher risk in terms of short-term price fluctuations for STVN.Check ATR's competition here
Bausch + Lomb Corporation (NYSE: BLCO)
STVN vs BLCO Comparison August 2026
Stevanato Group S.p.A. (NYSE: STVN) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, STVN stands at 5.9B. In comparison, BLCO has a market cap of 6.2B. Regarding current trading prices, STVN is priced at $22.03 on the NYSE, while BLCO trades at $17.39.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
STVN currently has a P/E ratio of 32.92, whereas BLCO's P/E ratio is 26.85. In terms of profitability, STVN's ROE is +0.09%, compared to BLCO's ROE of -0.03%. Regarding short-term risk, STVN is more volatile compared to BLCO. This indicates higher risk in terms of short-term price fluctuations for STVN.Check BLCO's competition here
Teleflex Incorporated (NYSE: TFX)
STVN vs TFX Comparison August 2026
Stevanato Group S.p.A. (NYSE: STVN) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, STVN stands at 5.9B. In comparison, TFX has a market cap of 6B. Regarding current trading prices, STVN is priced at $22.03 on the NYSE, while TFX trades at $136.74.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
STVN currently has a P/E ratio of 32.92, whereas TFX's P/E ratio is 15.54. In terms of profitability, STVN's ROE is +0.09%, compared to TFX's ROE of -0.32%. Regarding short-term risk, STVN is more volatile compared to TFX. This indicates higher risk in terms of short-term price fluctuations for STVN.Check TFX's competition here
Merit Medical Systems, Inc. (NASDAQ: MMSI)
STVN vs MMSI Comparison August 2026
Stevanato Group S.p.A. (NYSE: STVN) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, STVN stands at 5.9B. In comparison, MMSI has a market cap of 5.5B. Regarding current trading prices, STVN is priced at $22.03 on the NYSE, while MMSI trades at $90.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
STVN currently has a P/E ratio of 32.92, whereas MMSI's P/E ratio is 23.52. In terms of profitability, STVN's ROE is +0.09%, compared to MMSI's ROE of +0.09%. Regarding short-term risk, STVN is more volatile compared to MMSI. This indicates higher risk in terms of short-term price fluctuations for STVN.Check MMSI's competition here
ICU Medical, Inc. (NASDAQ: ICUI)
STVN vs ICUI Comparison August 2026
Stevanato Group S.p.A. (NYSE: STVN) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, STVN stands at 5.9B. In comparison, ICUI has a market cap of 4.7B. Regarding current trading prices, STVN is priced at $22.03 on the NYSE, while ICUI trades at $186.58.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
STVN currently has a P/E ratio of 32.92, whereas ICUI's P/E ratio is 23.38. In terms of profitability, STVN's ROE is +0.09%, compared to ICUI's ROE of +0.01%. Regarding short-term risk, STVN is more volatile compared to ICUI. This indicates higher risk in terms of short-term price fluctuations for STVN.Check ICUI's competition here
Envista Holdings Corp (NYSE: NVST)
STVN vs NVST Comparison August 2026
Stevanato Group S.p.A. (NYSE: STVN) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, STVN stands at 5.9B. In comparison, NVST has a market cap of 4.5B. Regarding current trading prices, STVN is priced at $22.03 on the NYSE, while NVST trades at $27.29.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
STVN currently has a P/E ratio of 32.92, whereas NVST's P/E ratio is 18.93. In terms of profitability, STVN's ROE is +0.09%, compared to NVST's ROE of +0.04%. Regarding short-term risk, STVN is more volatile compared to NVST. This indicates higher risk in terms of short-term price fluctuations for STVN.Check NVST's competition here
Pulse Biosciences, Inc. (NASDAQ: PLSE)
STVN vs PLSE Comparison August 2026
Stevanato Group S.p.A. (NYSE: STVN) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, STVN stands at 5.9B. In comparison, PLSE has a market cap of 3.3B. Regarding current trading prices, STVN is priced at $22.03 on the NYSE, while PLSE trades at $48.06.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
STVN currently has a P/E ratio of 32.92, whereas PLSE's P/E ratio is -39.85. In terms of profitability, STVN's ROE is +0.09%, compared to PLSE's ROE of -0.94%. Regarding short-term risk, STVN is less volatile compared to PLSE. This indicates lower risk in terms of short-term price fluctuations for STVN.Check PLSE's competition here
AtriCure, Inc. (NASDAQ: ATRC)
STVN vs ATRC Comparison August 2026
Stevanato Group S.p.A. (NYSE: STVN) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, STVN stands at 5.9B. In comparison, ATRC has a market cap of 2.4B. Regarding current trading prices, STVN is priced at $22.03 on the NYSE, while ATRC trades at $47.39.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
STVN currently has a P/E ratio of 32.92, whereas ATRC's P/E ratio is 1478.57. In terms of profitability, STVN's ROE is +0.09%, compared to ATRC's ROE of +0.02%. Regarding short-term risk, STVN is more volatile compared to ATRC. This indicates higher risk in terms of short-term price fluctuations for STVN.Check ATRC's competition here
DENTSPLY SIRONA Inc. (NASDAQ: XRAY)
STVN vs XRAY Comparison August 2026
Stevanato Group S.p.A. (NYSE: STVN) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, STVN stands at 5.9B. In comparison, XRAY has a market cap of 2.2B. Regarding current trading prices, STVN is priced at $22.03 on the NYSE, while XRAY trades at $10.87.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
STVN currently has a P/E ratio of 32.92, whereas XRAY's P/E ratio is 7.71. In terms of profitability, STVN's ROE is +0.09%, compared to XRAY's ROE of -0.40%. Regarding short-term risk, STVN is more volatile compared to XRAY. This indicates higher risk in terms of short-term price fluctuations for STVN.Check XRAY's competition here
LeMaitre Vascular, Inc. (NASDAQ: LMAT)
STVN vs LMAT Comparison August 2026
Stevanato Group S.p.A. (NYSE: STVN) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, STVN stands at 5.9B. In comparison, LMAT has a market cap of 1.9B. Regarding current trading prices, STVN is priced at $22.03 on the NYSE, while LMAT trades at $82.86.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
STVN currently has a P/E ratio of 32.92, whereas LMAT's P/E ratio is 30.83. In terms of profitability, STVN's ROE is +0.09%, compared to LMAT's ROE of +0.16%. Regarding short-term risk, STVN is more volatile compared to LMAT. This indicates higher risk in terms of short-term price fluctuations for STVN.Check LMAT's competition here
BioLife Solutions, Inc. (NASDAQ: BLFS)
STVN vs BLFS Comparison August 2026
Stevanato Group S.p.A. (NYSE: STVN) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, STVN stands at 5.9B. In comparison, BLFS has a market cap of 1.8B. Regarding current trading prices, STVN is priced at $22.03 on the NYSE, while BLFS trades at $37.57.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
STVN currently has a P/E ratio of 32.92, whereas BLFS's P/E ratio is -172.56. In terms of profitability, STVN's ROE is +0.09%, compared to BLFS's ROE of +0.13%. Regarding short-term risk, STVN is less volatile compared to BLFS. This indicates lower risk in terms of short-term price fluctuations for STVN.Check BLFS's competition here
Azenta, Inc. (NASDAQ: AZTA)
STVN vs AZTA Comparison August 2026
Stevanato Group S.p.A. (NYSE: STVN) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, STVN stands at 5.9B. In comparison, AZTA has a market cap of 1.6B. Regarding current trading prices, STVN is priced at $22.03 on the NYSE, while AZTA trades at $36.89.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
STVN currently has a P/E ratio of 32.92, whereas AZTA's P/E ratio is 84.81. In terms of profitability, STVN's ROE is +0.09%, compared to AZTA's ROE of -0.08%. Regarding short-term risk, STVN is less volatile compared to AZTA. This indicates lower risk in terms of short-term price fluctuations for STVN.Check AZTA's competition here
Kestra Medical Technologies, Ltd. (NASDAQ: KMTS)
STVN vs KMTS Comparison August 2026
Stevanato Group S.p.A. (NYSE: STVN) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, STVN stands at 5.9B. In comparison, KMTS has a market cap of 1.6B. Regarding current trading prices, STVN is priced at $22.03 on the NYSE, while KMTS trades at $27.66.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
STVN currently has a P/E ratio of 32.92, whereas KMTS's P/E ratio is -11.83. In terms of profitability, STVN's ROE is +0.09%, compared to KMTS's ROE of -0.59%. Regarding short-term risk, STVN is less volatile compared to KMTS. This indicates lower risk in terms of short-term price fluctuations for STVN.Check KMTS's competition here
STAAR Surgical Company (NASDAQ: STAA)
STVN vs STAA Comparison August 2026
Stevanato Group S.p.A. (NYSE: STVN) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, STVN stands at 5.9B. In comparison, STAA has a market cap of 1.2B. Regarding current trading prices, STVN is priced at $22.03 on the NYSE, while STAA trades at $23.55.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
STVN currently has a P/E ratio of 32.92, whereas STAA's P/E ratio is 43.26. In terms of profitability, STVN's ROE is +0.09%, compared to STAA's ROE of +0.01%. Regarding short-term risk, STVN is less volatile compared to STAA. This indicates lower risk in terms of short-term price fluctuations for STVN.Check STAA's competition here
QuidelOrtho Corporation (NASDAQ: QDEL)
STVN vs QDEL Comparison August 2026
Stevanato Group S.p.A. (NYSE: STVN) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, STVN stands at 5.9B. In comparison, QDEL has a market cap of 941M. Regarding current trading prices, STVN is priced at $22.03 on the NYSE, while QDEL trades at $14.77.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
STVN currently has a P/E ratio of 32.92, whereas QDEL's P/E ratio is 10.30. In terms of profitability, STVN's ROE is +0.09%, compared to QDEL's ROE of -0.55%. Regarding short-term risk, STVN is less volatile compared to QDEL. This indicates lower risk in terms of short-term price fluctuations for STVN.Check QDEL's competition here
Atrion Corporation (NASDAQ: ATRI)
STVN vs ATRI Comparison August 2026
Stevanato Group S.p.A. (NYSE: STVN) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, STVN stands at 5.9B. In comparison, ATRI has a market cap of 809.4M. Regarding current trading prices, STVN is priced at $22.03 on the NYSE, while ATRI trades at $459.92.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
STVN currently has a P/E ratio of 32.92, whereas ATRI's P/E ratio is 64.50. In terms of profitability, STVN's ROE is +0.09%, compared to ATRI's ROE of +0.08%. Regarding short-term risk, STVN is more volatile compared to ATRI. This indicates higher risk in terms of short-term price fluctuations for STVN.Check ATRI's competition here
AngioDynamics, Inc. (NASDAQ: ANGO)
STVN vs ANGO Comparison August 2026
Stevanato Group S.p.A. (NYSE: STVN) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, STVN stands at 5.9B. In comparison, ANGO has a market cap of 664.2M. Regarding current trading prices, STVN is priced at $22.03 on the NYSE, while ANGO trades at $15.89.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
STVN currently has a P/E ratio of 32.92, whereas ANGO's P/E ratio is -41.21. In terms of profitability, STVN's ROE is +0.09%, compared to ANGO's ROE of -0.21%. Regarding short-term risk, STVN is more volatile compared to ANGO. This indicates higher risk in terms of short-term price fluctuations for STVN.Check ANGO's competition here
Anbio Biotechnology Class A Ordinary Shares (NASDAQ: NNNN)
STVN vs NNNN Comparison August 2026
Stevanato Group S.p.A. (NYSE: STVN) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, STVN stands at 5.9B. In comparison, NNNN has a market cap of 366.5M. Regarding current trading prices, STVN is priced at $22.03 on the NYSE, while NNNN trades at $7.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
STVN currently has a P/E ratio of 32.92, whereas NNNN's P/E ratio is 120.66. In terms of profitability, STVN's ROE is +0.09%, compared to NNNN's ROE of +0.27%. Regarding short-term risk, STVN is less volatile compared to NNNN. This indicates lower risk in terms of short-term price fluctuations for STVN.Check NNNN's competition here
Sanara MedTech Inc. (NASDAQ: SMTI)
STVN vs SMTI Comparison August 2026
Stevanato Group S.p.A. (NYSE: STVN) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, STVN stands at 5.9B. In comparison, SMTI has a market cap of 315.1M. Regarding current trading prices, STVN is priced at $22.03 on the NYSE, while SMTI trades at $34.23.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
STVN currently has a P/E ratio of 32.92, whereas SMTI's P/E ratio is -571.33. In terms of profitability, STVN's ROE is +0.09%, compared to SMTI's ROE of -4.74%. Regarding short-term risk, STVN is more volatile compared to SMTI. This indicates higher risk in terms of short-term price fluctuations for STVN.Check SMTI's competition here
OraSure Technologies, Inc. (NASDAQ: OSUR)
STVN vs OSUR Comparison August 2026
Stevanato Group S.p.A. (NYSE: STVN) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, STVN stands at 5.9B. In comparison, OSUR has a market cap of 258.2M. Regarding current trading prices, STVN is priced at $22.03 on the NYSE, while OSUR trades at $3.73.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
STVN currently has a P/E ratio of 32.92, whereas OSUR's P/E ratio is -6.82. In terms of profitability, STVN's ROE is +0.09%, compared to OSUR's ROE of -0.15%. Regarding short-term risk, STVN is more volatile compared to OSUR. This indicates higher risk in terms of short-term price fluctuations for STVN.Check OSUR's competition here
InfuSystem Holdings, Inc. (AMEX: INFU)
STVN vs INFU Comparison August 2026
Stevanato Group S.p.A. (NYSE: STVN) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, STVN stands at 5.9B. In comparison, INFU has a market cap of 245.8M. Regarding current trading prices, STVN is priced at $22.03 on the NYSE, while INFU trades at $12.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
STVN currently has a P/E ratio of 32.92, whereas INFU's P/E ratio is 29.71. In terms of profitability, STVN's ROE is +0.09%, compared to INFU's ROE of +0.15%. Regarding short-term risk, STVN is more volatile compared to INFU. This indicates higher risk in terms of short-term price fluctuations for STVN.Check INFU's competition here
Utah Medical Products, Inc. (NASDAQ: UTMD)
STVN vs UTMD Comparison August 2026
Stevanato Group S.p.A. (NYSE: STVN) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, STVN stands at 5.9B. In comparison, UTMD has a market cap of 229.6M. Regarding current trading prices, STVN is priced at $22.03 on the NYSE, while UTMD trades at $72.79.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
STVN currently has a P/E ratio of 32.92, whereas UTMD's P/E ratio is 21.34. In terms of profitability, STVN's ROE is +0.09%, compared to UTMD's ROE of +0.09%. Regarding short-term risk, STVN is more volatile compared to UTMD. This indicates higher risk in terms of short-term price fluctuations for STVN.Check UTMD's competition here
Pro-Dex, Inc. (NASDAQ: PDEX)
STVN vs PDEX Comparison August 2026
Stevanato Group S.p.A. (NYSE: STVN) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, STVN stands at 5.9B. In comparison, PDEX has a market cap of 213.7M. Regarding current trading prices, STVN is priced at $22.03 on the NYSE, while PDEX trades at $67.05.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
STVN currently has a P/E ratio of 32.92, whereas PDEX's P/E ratio is 23.57. In terms of profitability, STVN's ROE is +0.09%, compared to PDEX's ROE of +0.29%. Regarding short-term risk, STVN is more volatile compared to PDEX. This indicates higher risk in terms of short-term price fluctuations for STVN.Check PDEX's competition here
KORU Medical Systems, Inc. (NASDAQ: KRMD)
STVN vs KRMD Comparison August 2026
Stevanato Group S.p.A. (NYSE: STVN) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, STVN stands at 5.9B. In comparison, KRMD has a market cap of 152.5M. Regarding current trading prices, STVN is priced at $22.03 on the NYSE, while KRMD trades at $3.31.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
STVN currently has a P/E ratio of 32.92, whereas KRMD's P/E ratio is -83.00. In terms of profitability, STVN's ROE is +0.09%, compared to KRMD's ROE of -0.11%. Regarding short-term risk, STVN is more volatile compared to KRMD. This indicates higher risk in terms of short-term price fluctuations for STVN.Check KRMD's competition here
Microbot Medical Inc. (NASDAQ: MBOT)
STVN vs MBOT Comparison August 2026
Stevanato Group S.p.A. (NYSE: STVN) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, STVN stands at 5.9B. In comparison, MBOT has a market cap of 70.6M. Regarding current trading prices, STVN is priced at $22.03 on the NYSE, while MBOT trades at $1.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
STVN currently has a P/E ratio of 32.92, whereas MBOT's P/E ratio is -5.96. In terms of profitability, STVN's ROE is +0.09%, compared to MBOT's ROE of -0.22%. Regarding short-term risk, STVN is less volatile compared to MBOT. This indicates lower risk in terms of short-term price fluctuations for STVN.Check MBOT's competition here
Akoya Biosciences, Inc. (NASDAQ: AKYA)
STVN vs AKYA Comparison August 2026
Stevanato Group S.p.A. (NYSE: STVN) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, STVN stands at 5.9B. In comparison, AKYA has a market cap of 64.4M. Regarding current trading prices, STVN is priced at $22.03 on the NYSE, while AKYA trades at $1.29.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
STVN currently has a P/E ratio of 32.92, whereas AKYA's P/E ratio is -1.34. In terms of profitability, STVN's ROE is +0.09%, compared to AKYA's ROE of -1.80%. Regarding short-term risk, STVN is more volatile compared to AKYA. This indicates higher risk in terms of short-term price fluctuations for STVN.Check AKYA's competition here
Daxor Corporation (NASDAQ: DXR)
STVN vs DXR Comparison August 2026
Stevanato Group S.p.A. (NYSE: STVN) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, STVN stands at 5.9B. In comparison, DXR has a market cap of 60.1M. Regarding current trading prices, STVN is priced at $22.03 on the NYSE, while DXR trades at $10.25.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
STVN currently has a P/E ratio of 32.92, whereas DXR's P/E ratio is 5.67. In terms of profitability, STVN's ROE is +0.09%, compared to DXR's ROE of +0.22%. Regarding short-term risk, STVN is more volatile compared to DXR. This indicates higher risk in terms of short-term price fluctuations for STVN.Check DXR's competition here
SkyAI, Inc. (NASDAQ: STSS)
STVN vs STSS Comparison August 2026
Stevanato Group S.p.A. (NYSE: STVN) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, STVN stands at 5.9B. In comparison, STSS has a market cap of 53.7M. Regarding current trading prices, STVN is priced at $22.03 on the NYSE, while STSS trades at $1.27.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
STVN currently has a P/E ratio of 32.92, whereas STSS's P/E ratio is -0.02. In terms of profitability, STVN's ROE is +0.09%, compared to STSS's ROE of -1.54%. Regarding short-term risk, STVN is less volatile compared to STSS. This indicates lower risk in terms of short-term price fluctuations for STVN.Check STSS's competition here
Nephros, Inc. (NASDAQ: NEPH)
STVN vs NEPH Comparison August 2026
Stevanato Group S.p.A. (NYSE: STVN) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, STVN stands at 5.9B. In comparison, NEPH has a market cap of 51.7M. Regarding current trading prices, STVN is priced at $22.03 on the NYSE, while NEPH trades at $4.43.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
STVN currently has a P/E ratio of 32.92, whereas NEPH's P/E ratio is 79.33. In terms of profitability, STVN's ROE is +0.09%, compared to NEPH's ROE of +0.16%. Regarding short-term risk, STVN is less volatile compared to NEPH. This indicates lower risk in terms of short-term price fluctuations for STVN.Check NEPH's competition here
Singular Genomics Systems, Inc. (NASDAQ: OMIC)
STVN vs OMIC Comparison August 2026
Stevanato Group S.p.A. (NYSE: STVN) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, STVN stands at 5.9B. In comparison, OMIC has a market cap of 50.8M. Regarding current trading prices, STVN is priced at $22.03 on the NYSE, while OMIC trades at $20.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
STVN currently has a P/E ratio of 32.92, whereas OMIC's P/E ratio is -0.58. In terms of profitability, STVN's ROE is +0.09%, compared to OMIC's ROE of -0.43%. Regarding short-term risk, STVN is more volatile compared to OMIC. This indicates higher risk in terms of short-term price fluctuations for STVN.Check OMIC's competition here
GlucoTrack, Inc. (NASDAQ: IGAP)
STVN vs IGAP Comparison August 2026
Stevanato Group S.p.A. (NYSE: STVN) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, STVN stands at 5.9B. In comparison, IGAP has a market cap of 50.2M. Regarding current trading prices, STVN is priced at $22.03 on the NYSE, while IGAP trades at $3.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
STVN currently has a P/E ratio of 32.92, whereas IGAP's P/E ratio is -10.52. In terms of profitability, STVN's ROE is +0.09%, compared to IGAP's ROE of +1.80%. Regarding short-term risk, STVN is more volatile compared to IGAP. This indicates higher risk in terms of short-term price fluctuations for STVN.Check IGAP's competition here
Precision Optics Corporation, Inc. (NASDAQ: POCI)
STVN vs POCI Comparison August 2026
Stevanato Group S.p.A. (NYSE: STVN) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, STVN stands at 5.9B. In comparison, POCI has a market cap of 48.6M. Regarding current trading prices, STVN is priced at $22.03 on the NYSE, while POCI trades at $4.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
STVN currently has a P/E ratio of 32.92, whereas POCI's P/E ratio is -6.17. In terms of profitability, STVN's ROE is +0.09%, compared to POCI's ROE of -0.37%. Regarding short-term risk, STVN is more volatile compared to POCI. This indicates higher risk in terms of short-term price fluctuations for STVN.Check POCI's competition here
Milestone Scientific Inc. (AMEX: MLSS)
STVN vs MLSS Comparison August 2026
Stevanato Group S.p.A. (NYSE: STVN) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, STVN stands at 5.9B. In comparison, MLSS has a market cap of 42.4M. Regarding current trading prices, STVN is priced at $22.03 on the NYSE, while MLSS trades at $0.46.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
STVN currently has a P/E ratio of 32.92, whereas MLSS's P/E ratio is -7.99. In terms of profitability, STVN's ROE is +0.09%, compared to MLSS's ROE of -1.49%. Regarding short-term risk, STVN is more volatile compared to MLSS. This indicates higher risk in terms of short-term price fluctuations for STVN.Check MLSS's competition here
Harvard Bioscience, Inc. (NASDAQ: HBIO)
STVN vs HBIO Comparison August 2026
Stevanato Group S.p.A. (NYSE: STVN) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, STVN stands at 5.9B. In comparison, HBIO has a market cap of 31.9M. Regarding current trading prices, STVN is priced at $22.03 on the NYSE, while HBIO trades at $7.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
STVN currently has a P/E ratio of 32.92, whereas HBIO's P/E ratio is -19.67. In terms of profitability, STVN's ROE is +0.09%, compared to HBIO's ROE of -0.92%. Regarding short-term risk, STVN is less volatile compared to HBIO. This indicates lower risk in terms of short-term price fluctuations for STVN.Check HBIO's competition here
SmileDirectClub, Inc. (NASDAQ: SDC)
STVN vs SDC Comparison August 2026
Stevanato Group S.p.A. (NYSE: STVN) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, STVN stands at 5.9B. In comparison, SDC has a market cap of 29.1M. Regarding current trading prices, STVN is priced at $22.03 on the NYSE, while SDC trades at $0.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
STVN currently has a P/E ratio of 32.92, whereas SDC's P/E ratio is -0.03. In terms of profitability, STVN's ROE is +0.09%, compared to SDC's ROE of -1.96%. Regarding short-term risk, STVN is less volatile compared to SDC. This indicates lower risk in terms of short-term price fluctuations for STVN.Check SDC's competition here
Invacare Corporation (NYSE: IVC)
STVN vs IVC Comparison August 2026
Stevanato Group S.p.A. (NYSE: STVN) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, STVN stands at 5.9B. In comparison, IVC has a market cap of 24.9M. Regarding current trading prices, STVN is priced at $22.03 on the NYSE, while IVC trades at $0.66.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
STVN currently has a P/E ratio of 32.92, whereas IVC's P/E ratio is -0.79. In terms of profitability, STVN's ROE is +0.09%, compared to IVC's ROE of -0.46%. Regarding short-term risk, STVN is less volatile compared to IVC. This indicates lower risk in terms of short-term price fluctuations for STVN.Check IVC's competition here
Jin Medical International Ltd. (NASDAQ: ZJYL)
STVN vs ZJYL Comparison August 2026
Stevanato Group S.p.A. (NYSE: STVN) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, STVN stands at 5.9B. In comparison, ZJYL has a market cap of 24.1M. Regarding current trading prices, STVN is priced at $22.03 on the NYSE, while ZJYL trades at $3.14.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
STVN currently has a P/E ratio of 32.92, whereas ZJYL's P/E ratio is 19.25. In terms of profitability, STVN's ROE is +0.09%, compared to ZJYL's ROE of +0.04%. Regarding short-term risk, STVN is less volatile compared to ZJYL. This indicates lower risk in terms of short-term price fluctuations for STVN.Check ZJYL's competition here
Retractable Technologies, Inc. (AMEX: RVP)
STVN vs RVP Comparison August 2026
Stevanato Group S.p.A. (NYSE: STVN) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, STVN stands at 5.9B. In comparison, RVP has a market cap of 21.7M. Regarding current trading prices, STVN is priced at $22.03 on the NYSE, while RVP trades at $0.72.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
STVN currently has a P/E ratio of 32.92, whereas RVP's P/E ratio is -2.20. In terms of profitability, STVN's ROE is +0.09%, compared to RVP's ROE of -0.05%. Regarding short-term risk, STVN is more volatile compared to RVP. This indicates higher risk in terms of short-term price fluctuations for STVN.Check RVP's competition here
Regentis Biomaterials Ltd. (AMEX: RGNT)
STVN vs RGNT Comparison August 2026
Stevanato Group S.p.A. (NYSE: STVN) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, STVN stands at 5.9B. In comparison, RGNT has a market cap of 15.6M. Regarding current trading prices, STVN is priced at $22.03 on the NYSE, while RGNT trades at $2.15.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
STVN currently has a P/E ratio of 32.92, whereas RGNT's P/E ratio is -0.09. In terms of profitability, STVN's ROE is +0.09%, compared to RGNT's ROE of N/A. Regarding short-term risk, STVN is less volatile compared to RGNT. This indicates lower risk in terms of short-term price fluctuations for STVN.Check RGNT's competition here
Femasys Inc. (NASDAQ: FEMY)
STVN vs FEMY Comparison August 2026
Stevanato Group S.p.A. (NYSE: STVN) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, STVN stands at 5.9B. In comparison, FEMY has a market cap of 7.9M. Regarding current trading prices, STVN is priced at $22.03 on the NYSE, while FEMY trades at $2.73.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
STVN currently has a P/E ratio of 32.92, whereas FEMY's P/E ratio is -7.21. In terms of profitability, STVN's ROE is +0.09%, compared to FEMY's ROE of -2.26%. Regarding short-term risk, STVN is less volatile compared to FEMY. This indicates lower risk in terms of short-term price fluctuations for STVN.Check FEMY's competition here
NanoString Technologies, Inc. (NASDAQ: NSTG)
STVN vs NSTG Comparison August 2026
Stevanato Group S.p.A. (NYSE: STVN) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, STVN stands at 5.9B. In comparison, NSTG has a market cap of 5.1M. Regarding current trading prices, STVN is priced at $22.03 on the NYSE, while NSTG trades at $0.11.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
STVN currently has a P/E ratio of 32.92, whereas NSTG's P/E ratio is -0.03. In terms of profitability, STVN's ROE is +0.09%, compared to NSTG's ROE of -1.43%. Regarding short-term risk, STVN is less volatile compared to NSTG. This indicates lower risk in terms of short-term price fluctuations for STVN.Check NSTG's competition here
Lucyd, Inc (NASDAQ: LUCY)
STVN vs LUCY Comparison August 2026
Stevanato Group S.p.A. (NYSE: STVN) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, STVN stands at 5.9B. In comparison, LUCY has a market cap of 4.4M. Regarding current trading prices, STVN is priced at $22.03 on the NYSE, while LUCY trades at $0.67.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
STVN currently has a P/E ratio of 32.92, whereas LUCY's P/E ratio is -0.41. In terms of profitability, STVN's ROE is +0.09%, compared to LUCY's ROE of -0.89%. Regarding short-term risk, STVN is less volatile compared to LUCY. This indicates lower risk in terms of short-term price fluctuations for STVN.Check LUCY's competition here
Predictive Oncology Inc. (NASDAQ: POAI)
STVN vs POAI Comparison August 2026
Stevanato Group S.p.A. (NYSE: STVN) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, STVN stands at 5.9B. In comparison, POAI has a market cap of 3.6M. Regarding current trading prices, STVN is priced at $22.03 on the NYSE, while POAI trades at $4.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
STVN currently has a P/E ratio of 32.92, whereas POAI's P/E ratio is -0.03. In terms of profitability, STVN's ROE is +0.09%, compared to POAI's ROE of -21.19%. Regarding short-term risk, STVN is less volatile compared to POAI. This indicates lower risk in terms of short-term price fluctuations for STVN.Check POAI's competition here
NEXGEL, Inc. (NASDAQ: NXGL)
STVN vs NXGL Comparison August 2026
Stevanato Group S.p.A. (NYSE: STVN) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, STVN stands at 5.9B. In comparison, NXGL has a market cap of 3.3M. Regarding current trading prices, STVN is priced at $22.03 on the NYSE, while NXGL trades at $0.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
STVN currently has a P/E ratio of 32.92, whereas NXGL's P/E ratio is -0.55. In terms of profitability, STVN's ROE is +0.09%, compared to NXGL's ROE of -1.33%. Regarding short-term risk, STVN is less volatile compared to NXGL. This indicates lower risk in terms of short-term price fluctuations for STVN.Check NXGL's competition here
GlucoTrack, Inc. (NASDAQ: GCTK)
STVN vs GCTK Comparison August 2026
Stevanato Group S.p.A. (NYSE: STVN) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, STVN stands at 5.9B. In comparison, GCTK has a market cap of 2.7M. Regarding current trading prices, STVN is priced at $22.03 on the NYSE, while GCTK trades at $0.34.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
STVN currently has a P/E ratio of 32.92, whereas GCTK's P/E ratio is -0.02. In terms of profitability, STVN's ROE is +0.09%, compared to GCTK's ROE of -21.36%. Regarding short-term risk, STVN is less volatile compared to GCTK. This indicates lower risk in terms of short-term price fluctuations for STVN.Check GCTK's competition here
Meihua International Medical Technologies Co., Ltd. (NASDAQ: MHUA)
STVN vs MHUA Comparison August 2026
Stevanato Group S.p.A. (NYSE: STVN) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, STVN stands at 5.9B. In comparison, MHUA has a market cap of 2.4M. Regarding current trading prices, STVN is priced at $22.03 on the NYSE, while MHUA trades at $7.61.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
STVN currently has a P/E ratio of 32.92, whereas MHUA's P/E ratio is 0.25. In terms of profitability, STVN's ROE is +0.09%, compared to MHUA's ROE of +0.07%. Regarding short-term risk, STVN is more volatile compared to MHUA. This indicates higher risk in terms of short-term price fluctuations for STVN.Check MHUA's competition here
G Medical Innovations Holdings Ltd (NASDAQ: GMVD)
STVN vs GMVD Comparison August 2026
Stevanato Group S.p.A. (NYSE: STVN) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, STVN stands at 5.9B. In comparison, GMVD has a market cap of 1.8M. Regarding current trading prices, STVN is priced at $22.03 on the NYSE, while GMVD trades at $0.18.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
STVN currently has a P/E ratio of 32.92, whereas GMVD's P/E ratio is -0.01. In terms of profitability, STVN's ROE is +0.09%, compared to GMVD's ROE of +2.09%. Regarding short-term risk, STVN is less volatile compared to GMVD. This indicates lower risk in terms of short-term price fluctuations for STVN.Check GMVD's competition here
G Medical Innovations Holdings Ltd (NASDAQ: GMVDW)
STVN vs GMVDW Comparison August 2026
Stevanato Group S.p.A. (NYSE: STVN) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, STVN stands at 5.9B. In comparison, GMVDW has a market cap of 1.8M. Regarding current trading prices, STVN is priced at $22.03 on the NYSE, while GMVDW trades at $7.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
STVN currently has a P/E ratio of 32.92, whereas GMVDW's P/E ratio is N/A. In terms of profitability, STVN's ROE is +0.09%, compared to GMVDW's ROE of +2.09%. Regarding short-term risk, STVN is less volatile compared to GMVDW. This indicates lower risk in terms of short-term price fluctuations for STVN.Check GMVDW's competition here
NEXGEL, Inc. (NASDAQ: NXGLW)
STVN vs NXGLW Comparison August 2026
Stevanato Group S.p.A. (NYSE: STVN) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, STVN stands at 5.9B. In comparison, NXGLW has a market cap of 1.5M. Regarding current trading prices, STVN is priced at $22.03 on the NYSE, while NXGLW trades at $0.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
STVN currently has a P/E ratio of 32.92, whereas NXGLW's P/E ratio is -0.05. In terms of profitability, STVN's ROE is +0.09%, compared to NXGLW's ROE of -1.33%. Regarding short-term risk, STVN is more volatile compared to NXGLW. This indicates higher risk in terms of short-term price fluctuations for STVN.Check NXGLW's competition here
Avinger, Inc. (NASDAQ: AVGR)
STVN vs AVGR Comparison August 2026
Stevanato Group S.p.A. (NYSE: STVN) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, STVN stands at 5.9B. In comparison, AVGR has a market cap of 1.5M. Regarding current trading prices, STVN is priced at $22.03 on the NYSE, while AVGR trades at $0.47.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
STVN currently has a P/E ratio of 32.92, whereas AVGR's P/E ratio is -0.05. In terms of profitability, STVN's ROE is +0.09%, compared to AVGR's ROE of +17.82%. Regarding short-term risk, STVN is less volatile compared to AVGR. This indicates lower risk in terms of short-term price fluctuations for STVN.Check AVGR's competition here
Lucyd, Inc (NASDAQ: LUCYW)
STVN vs LUCYW Comparison August 2026
Stevanato Group S.p.A. (NYSE: STVN) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, STVN stands at 5.9B. In comparison, LUCYW has a market cap of 296.1K. Regarding current trading prices, STVN is priced at $22.03 on the NYSE, while LUCYW trades at $0.06.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
STVN currently has a P/E ratio of 32.92, whereas LUCYW's P/E ratio is N/A. In terms of profitability, STVN's ROE is +0.09%, compared to LUCYW's ROE of -0.89%. Regarding short-term risk, STVN is less volatile compared to LUCYW. This indicates lower risk in terms of short-term price fluctuations for STVN.Check LUCYW's competition here
Apria, Inc. (NASDAQ: APR)
STVN vs APR Comparison August 2026
Stevanato Group S.p.A. (NYSE: STVN) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, STVN stands at 5.9B. In comparison, APR has a market cap of 0. Regarding current trading prices, STVN is priced at $22.03 on the NYSE, while APR trades at $37.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
STVN currently has a P/E ratio of 32.92, whereas APR's P/E ratio is 22.59. In terms of profitability, STVN's ROE is +0.09%, compared to APR's ROE of +9.81%. Regarding short-term risk, STVN is more volatile compared to APR. This indicates higher risk in terms of short-term price fluctuations for STVN.Check APR's competition here
Hill-Rom Holdings, Inc. (NYSE: HRC)
STVN vs HRC Comparison August 2026
Stevanato Group S.p.A. (NYSE: STVN) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, STVN stands at 5.9B. In comparison, HRC has a market cap of 0. Regarding current trading prices, STVN is priced at $22.03 on the NYSE, while HRC trades at $155.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
STVN currently has a P/E ratio of 32.92, whereas HRC's P/E ratio is 41.92. In terms of profitability, STVN's ROE is +0.09%, compared to HRC's ROE of +0.14%. Regarding short-term risk, STVN is more volatile compared to HRC. This indicates higher risk in terms of short-term price fluctuations for STVN.Check HRC's competition here
IntriCon Corporation (NASDAQ: IIN)
STVN vs IIN Comparison August 2026
Stevanato Group S.p.A. (NYSE: STVN) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, STVN stands at 5.9B. In comparison, IIN has a market cap of 0. Regarding current trading prices, STVN is priced at $22.03 on the NYSE, while IIN trades at $24.23.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
STVN currently has a P/E ratio of 32.92, whereas IIN's P/E ratio is 226.45. In terms of profitability, STVN's ROE is +0.09%, compared to IIN's ROE of -0.00%. Regarding short-term risk, STVN is more volatile compared to IIN. This indicates higher risk in terms of short-term price fluctuations for STVN.Check IIN's competition here
Analogic Corporation (NASDAQ: ALOG)
STVN vs ALOG Comparison August 2026
Stevanato Group S.p.A. (NYSE: STVN) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, STVN stands at 5.9B. In comparison, ALOG has a market cap of 0. Regarding current trading prices, STVN is priced at $22.03 on the NYSE, while ALOG trades at $83.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
STVN currently has a P/E ratio of 32.92, whereas ALOG's P/E ratio is 40.93. In terms of profitability, STVN's ROE is +0.09%, compared to ALOG's ROE of -0.15%. Regarding short-term risk, STVN is more volatile compared to ALOG. This indicates higher risk in terms of short-term price fluctuations for STVN.Check ALOG's competition here
Invuity, Inc. (NASDAQ: IVTY)
STVN vs IVTY Comparison August 2026
Stevanato Group S.p.A. (NYSE: STVN) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, STVN stands at 5.9B. In comparison, IVTY has a market cap of 0. Regarding current trading prices, STVN is priced at $22.03 on the NYSE, while IVTY trades at $7.39.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
STVN currently has a P/E ratio of 32.92, whereas IVTY's P/E ratio is -3.80. In terms of profitability, STVN's ROE is +0.09%, compared to IVTY's ROE of -2.40%. Regarding short-term risk, STVN is more volatile compared to IVTY. This indicates higher risk in terms of short-term price fluctuations for STVN.Check IVTY's competition here
Antares Pharma, Inc. (NASDAQ: ATRS)
STVN vs ATRS Comparison August 2026
Stevanato Group S.p.A. (NYSE: STVN) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, STVN stands at 5.9B. In comparison, ATRS has a market cap of 0. Regarding current trading prices, STVN is priced at $22.03 on the NYSE, while ATRS trades at $5.59.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
STVN currently has a P/E ratio of 32.92, whereas ATRS's P/E ratio is 14.95. In terms of profitability, STVN's ROE is +0.09%, compared to ATRS's ROE of +0.31%. Regarding short-term risk, STVN is more volatile compared to ATRS. This indicates higher risk in terms of short-term price fluctuations for STVN.Check ATRS's competition here